CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced that new data from studies evaluating the Zoom Stroke Solution were presented at the Society of NeuroInterventional Surgery (SNIS) 2023 20th Annual Meeting in San Diego, Calif.
“We are pleased to see the results from these studies further supporting that the Zoom Stroke Solution is associated with improved procedural outcomes,” said Ariel Sutton, General Manager of Imperative Care’s Stroke business. “These findings are an important step forward in our continued efforts to build a strong body of clinical evidence and in our mission to innovate every aspect of the stroke thrombectomy procedure to improve patient outcomes.”
Intracranial .088” guide catheter positioning leads to improved first pass effect and shorter procedure times
Results from a multicenter study evaluating the association between .088” guide catheter positioning and final reperfusion in 428 patients who received an aspiration thrombectomy for ischemic stroke were presented by Mais Al-Fawaz, M.D., University of Kentucky.
Findings from the study demonstrated that .088” intracranial guide catheter placement in the petrous internal carotid artery (ICA) segment or further distal versus placement in the cervical ICA segment or more proximal was associated with:
- A significantly higher first pass effect (43.2% vs. 25.5%, p<0.001),
- A better rate of TICI≥2C reperfusion (71.2% vs. 65%, p=0.194),
- A significantly shorter median time from groin puncture to final reperfusion (21 minutes vs. 35.5 minutes, p<0.001), and
- A definitively lower total median number of passes (two vs. three, p<0.015).
“This multicenter analysis further supports the critical importance of intracranial positioning of the guide catheter in achieving a swift recanalization with higher first pass effect and lower procedural time in patients with large vessel occlusion stroke,” said a lead author of the study, Shahram Majidi, M.D., Mount Sinai.
“The Zoom 88 Large Distal Platform is the only 0.088" guide catheter that can access the intracranial anatomy and get closer to the clot,” said Jim Milburn, M.D., Ochsner Medical Center, an additional lead author of the study. “This has helped me gain even more control over my stroke procedures by allowing me to navigate to the clot more quickly and reduce the risk of clot shearing and distal embolism.”
Early data suggest Zoom RDL is safe and technically feasible across a range of neurointerventional procedures
Rami Z. Morsi, M.D., University of Chicago Medicine, presented results from an early single-center experience using the company’s Zoom RDL Radial Access Platform, the first radial access platform developed specifically for ischemic stroke treatment. Findings from the study showed that Zoom RDL is technically feasible and effective for complex neurointerventional procedures with low complication rates.
Preliminary data indicate the Zoom Aspiration Catheters are safe and highly effective in treating DVO
Data presented at the meeting suggests that endovascular thrombectomy may be beneficial in patients with distal vessel occlusion (DVO) stroke, with the study concluding that the Zoom Aspiration Catheters are safe and highly effective in treating DVOs. Results from a three-institution retrospective review of 78 acute stroke patients with DVOs who were treated with a Zoom Aspiration Catheter (Zoom 71, Zoom 55, Zoom 45, and Zoom 35) were presented by Daryl Goldman, M.D., Mount Sinai. These findings demonstrated that treatment with Zoom Aspiration Catheters resulted in high rates of reperfusion and fast procedure times, with low rates of symptomatic intracranial hemorrhage.
Other abstracts presented at SNIS showcase the clinical utility of Zoom Access and Aspiration Catheters
A benchtop analysis evaluating the effect of intracranial flow parameters on the left side of the brain using various guide catheters for aspiration thrombectomy was presented by Holly Berns, Ph.D. candidate, Northern Arizona University. The evaluation showed that distal placement of a Zoom 88 can translate to the same or better flow reduction than a balloon guide catheter positioned in the proximal ICA, without the additional time required to set up the balloon.
Additionally, data from a single-center evaluation presented by Sonam Thind, A.P.N., University of Chicago Medicine, showed that the Zoom 45 Aspiration Catheter was technically feasible, safe and effective for accessing the middle meningeal artery in patients with subdural hematomas.
About the Zoom Stroke Solution
The Zoom Stroke Solution is the complete stroke system from access through reperfusion for fast and effective clot removal for patients with acute ischemic stroke. The system includes the Zoom 88 Large Distal Platform and Zoom RDL Radial Access Platform for neurovascular access, four vessel-matched Zoom Aspiration Catheters, the Zoom Pump, the Zoom POD and accessories. All Zoom catheters are designed with the TRX™ Tip which provides 15% greater clot engagement area at the tip of the catheter1 and are designed to enable smooth tracking through challenging vasculature. For complete product information, including indications, contraindications, warnings, precautions and adverse events visit: http://bit.ly/2Vx0Qcf
About Imperative Care, Inc.
Imperative Care is a commercial-stage medical technology company researching and developing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. The company has four businesses focused on addressing specific gaps in treatment and care to make an impact across the entire patient journey. Imperative Care is based in Campbell, Calif. https://imperativecare.com.
1. Vargas J, Blalock J, Venkatraman A, et al Efficacy of beveled tip aspiration catheter in mechanical thrombectomy for acute ischemic stroke Journal of NeuroInterventional Surgery 2021;13:823-826.
+ Dr. Milburn is a paid consultant for Imperative Care.
+ Dr. Majidi is a paid consultant for Imperative Care.
+ The Northern Arizona University study was sponsored by Imperative Care.
